10x Genomics (NASDAQ:TXG – Get Free Report) and Mitesco (OTCMKTS:MITI – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for 10x Genomics and Mitesco, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 10 | 4 | 0 | 2.20 |
| Mitesco | 0 | 0 | 0 | 0 | 0.00 |
10x Genomics presently has a consensus price target of $28.92, suggesting a potential downside of 32.33%. Given 10x Genomics’ stronger consensus rating and higher possible upside, equities analysts plainly believe 10x Genomics is more favorable than Mitesco.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -3.55% | -2.86% | -2.23% |
| Mitesco | N/A | -2.18% | -2,982.65% |
Institutional and Insider Ownership
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 0.0% of Mitesco shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 4.9% of Mitesco shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares 10x Genomics and Mitesco”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $642.82 million | 8.44 | -$43.54 million | ($0.17) | -251.35 |
| Mitesco | $40,000.00 | 36.65 | $500,000.00 | ($0.33) | -0.21 |
Mitesco has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mitesco, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
10x Genomics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 4.95, meaning that its stock price is 395% more volatile than the S&P 500.
Summary
10x Genomics beats Mitesco on 8 of the 14 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Mitesco
Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
